LDS/Medical Tests/Sarcoma Gene Mutation, Fusion and Rearrangement Panel, NGS

Sarcoma Gene Mutation, Fusion and Rearrangement Panel, NGS

Sarcomas are malignant mesenchymal tumors arising from soft tissues and bones. Due to their rarity and heterogeneity, the accuracy of sarcoma histologic diagnosis is challenging. Therefore, identification of type-specific gene alterations plays an important role in the differential diagnosis of sarcomas, sarcoma types, benign mimics, and other tumor types.

Genomic translocations are present in approximately 20-30% of sarcomas and specific translocations and resultant fusion genes are associated with various subtypes of sarcomas. The PAX3/FOXO1 fusion gene is observed in alveolar rhabdomyosarcoma, the EWSR1-FLI1 fusion gene is associated with Ewing’s sarcoma and the SS18-SSX1/2 fusion gene is found in synovial sarcoma. The abnormal chimeric fusion proteins formed by translocations may disrupt normal transcription and growth control processes and are therefore believed to be responsible for tumorigenesis in most cases.

Ewing sarcoma belongs to a family of releated tumors that may arise in bones or soft tissues. The Ewing sarcoma family of tumors (EFT) includes Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors most commonly occur in the long bones of the extremities and in the pelvis. Symptoms include stiffness, pain, swelling, or tenderness of the bone or surrounding tissue. On the molecular level the EFT are associated with translocations of the EWS gene on chromosome 22 with one of several partner genes including FLI1, ERG, ETV1, E1A and FEV. Rhabdomyosarcoma is a highly malignant tumor derived from primitive mesenchymal cells. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas. In the alveolar form a chromosomal translocation fuses either the PAX3 gene on chromosome 2 or the PAX7 gene on chromosome 1 and FOXO1 gene on chromosome 13, resulting in either PAX3-FOXO1 or PAX7-FOXO1 fusion genes respectively. Synovial sarcoma (SS) is the malignant neoplasm arises in the synovial membranes of the joints and the synovial cells of the tendons and bursae. This tumor can occur in the deep soft tissue of the extremities, especially around the knee, abdominal wall and other trunk muscles. Histological subtypes of SS include biphasic tumors containing epithelia-like/spindle cells, monophasic tumors containing only spindle cells, and poorly differentiated tumors. A characteristic chromosomal translocation t(X;18)(p11;q11), seen in virtually all SS cases, fuses the SS18 gene on chromosome 18 with one of three homologous genes (SSX1, SSX2, or SSX4) on the X chromosome. 90–95% of SS carry chromosomal translocation-associated SS18-SSX1 or SS18-SSX2 fusion genes.

Panel Components

Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate somatic gene fusions. Targeted genes: ACTB, AHRR, ALK, ASPSCR1, ATF1, ATIC, BCOR, BRD3, BRD4, CAMTA1, CARS, CCNB3, CDH11, CDX1, CD63, CEP128, CIC, CITED2, CLTC, CNBP, COL1A1, COL1A2, COL3A1, COL6A3, CREB1, CREB3L1, CREB3L2, CSF1, CXorf67, C11orf95, DDIT3, DUX4, DVL2, EML4, EPC1, EP400, ERG, ETV1, ETV4, ETV6, EWSR1, FEV, FGFR1, FLI1, FN1, FOSB, FOXO1, FOXO4, FUS, GLI1, HAS2, HEY1, HMGA2, IRF2BP2, JAZF1, KIRREL, KLF17, LAMTOR1, LPP, MAML3, MBTD, MEAF6, MED12, MIR143HG, MKL2, MYH9, NAB2, NCOA1, NCOA2, NFATC2, NFIB, NOTCH1, NOTCH2, NR4A3, NTRK1, NTRK3, NUMA1, NUTM1, NUTM2B, OMD, OPHN1, PATZ1, PAX3, PAX7, PBX1, PBX3, PDGFB, PDPN, PHF1, PLAG1, PLPP3, POU5F1, PPFIBP1, PRDM10, PRKCA, PRKCB, PRKCD, RAB2A,RAD51B, RANBP2, RNF213, RRAGB, SEC31A, SERPINE1, SETBP1, SFMBT1, SMARCA5, SP3, SQSTM1, SRF, SRSF3, SSX1, SSX2, SSX4, SS18, SS18L1, STAT6, SUZ12, S100A10, TAF15, TCF12, TEAD1, TFE3, TFG, THRAP3, TPM3, TPM4, TPR, USP6, VCL, VGLL2, WT1, WWTR1, YAP1, YWHAE, ZC3H7B, ZFP36, and ZNF444.

  • For the diagnosis of benign or malignant mesenchymal tumors (sarcomas and their mimics)
  • For the differential diagnosis of sarcoma based on the observed gene fusions (eg, PAX3/FOXO1 gene fusion observed in alveolar rhabdomyosarcoma, EWSR1-FLI1 gene fusion for Ewing’s sarcoma, SS18-SSX1/2 gene fusion for synovial sarcoma)
  • When compared to FISH, molecular detection of sarcoma translocations requires less tumor sample and therefore more cost-effective screen

Positive

  • Fusion genes were detected. PAX3/FOXO1 fusion gene detected in alveolar rhabdomyosarcoma, EWSR1-FLI1 fusion gene in Ewing’s sarcoma, SS18-SSX1/2 fusion gene in synovial sarcoma. Any pathogenic variant or mutation can be supportive for diagnosis and disease management.

Negative

  • Fusion genes were not detected within the analyzed genes, or negative for pathogenic variants of mutations in analyzed genes.

Negative for mutations and fusion within the analyzed genes

Next-generation sequencing, Conventional sequencing.

Formalin-fixed, paraffin-embedded (FFPE) tissue.

Stability

  • Ambient: Indefinitely
  • Refrigerated: Indefinitely
Immunohistochemistry, H/E stain, Biopsy, Computed tomography (CT or CAT) scan, Magnetic resonance imaging (MRI), FISH, RT-PCR assays
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login